Researchers from Childrens National Medical Center have found that an alternate, escape replication process triggered by apoptosisthe process of cell death or cell suicideappears to be common in human herpesviruses (HHV). The findings have implications for better understanding of viruses and of disease conditions and treatments, like chemotherapy, that stimulate apoptosis. The study was published online, ahead of print, in the Journal of Virology.
HHV are linked to a range of childhood and adult diseases, including chickenpox, mononucleosis, roseola, cold sores, and genital sores, and can be particularly troublesome for patients who are immunosuppressed because they have cancer or AIDS. Some HHV types are so common as to be nearly universal in humans. A central feature is their ability to remain latent for long periods of time, and then reactivate after the latent phase. Previously, reactivation was attributed largely to waning immunity, immunosuppression, or exposure to certain inducing agents.
In this study, Childrens National researchers examined cell lines latently infected with several herpesviruses: HHV-4 or Epstein Barr Virus, the causative agent of mononucleosis; HHV-6A; HHV-6B, which causes the disease roseola in infants and infects almost all children in the first few years of life; HHV-7; and HHV-8 (or Kapsosis Sarcoma-associated Herpesvirus), to explore whether an alternate, apoptosis-induced replication program is a common feature of HHV biology. They found that apoptosis triggers an alternate replication pathway in each HHV type studied.
Â
Our findings suggest that most if not all HHV types can sense that the host cell is dying, which prompts them to launch an emergency replication process, says lead author Alka Prasad, PhD, a post-doctoral fellow in the Center for Cancer and Immunology Research of the Childrens Research Institute at Childrens National. Herpesviruses have genes that try to prevent apoptosis, but when the viruses cannot block the host cell from undergoing apoptosis, they apparently launch this alternate process to reproduce before the cell diessuggesting that these herpesviruses are not simply destructive cell-bombs but more nuanced organisms that engage in a dialogue with the host cell.
Â
The study also found that commonly used chemotherapy agents activate this replication process, indicating that these and other treatments that promote apoptosis may activate latent HHV.
Â
Our findings make great sense from an evolutionary point of view. If the viruses didnt have this emergency alternative way of reproducing then, if the cell they were living in died, they would have no chance of making additional viruses. With this alternative process, the viruses have a chance of reproducing. This study also helps explain some observations that previously did not quite fit, like why HHV seemed to be activated in conditions associated with apoptosis, says senior author Steven Zeichner, MD, PhD, Senior Investigator for Childrens Research Institute at Childrens National and Professor of Pediatrics and Microbiology at George Washington University. Clinically, these results suggest it may be beneficial to treat patients with antivirals against HHV when we expect apoptosis to be induced, such as in chemotherapy for cancer patients.
Â
These new findings build on earlier research led by Childrens National that showed HHV-8 to have an alternate replication path triggered when the host cell undergoes apoptosis and that this process generates a high volume of virus but with a lower infectivity rate.
Â
Source: Childrens National Medical Center
Comprehensive Strategies in Wound Care: Insights From Madhavi Ponnapalli, MD
November 22nd 2024Madhavi Ponnapalli, MD, discusses effective wound care strategies, including debridement techniques, offloading modalities, appropriate dressing selection, compression therapy, and nutritional needs for optimal healing outcomes.
The Leapfrog Group and the Positive Effect on Hospital Hand Hygiene
November 21st 2024The Leapfrog Group enhances hospital safety by publicizing hand hygiene performance, improving patient safety outcomes, and significantly reducing health care-associated infections through transparent standards and monitoring initiatives.
Managing Multimorbidity and Polypharmacy in HIV: Insights From Michelle S. Cespedes, MD, MS
November 20th 2024Michelle S. Cespedes, MD, MS, discusses the challenges of managing multimorbidity and polypharmacy in HIV treatment, emphasizing patient education, evolving guidelines, and real-world insights from the REPRIEVE study.
Longhorn Vaccines and Diagnostics to Showcase Breakthrough Vaccine Data at IDWeek 2024
November 19th 2024Longhorn Vaccines and Diagnostics revealed promising data on universal influenza vaccine LHNVD-110 and AMR sepsis vaccine LHNVD-303 at IDWeek 2024, addressing critical global health challenges.